Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma
Lisa Haas(Research Institute of Molecular Pathology), Anna C. Obenauf(Research Institute of Molecular Pathology), Olivier Michielin(SIB Swiss Institute of Bioinformatics), Tobias Neumann(Research Institute of Molecular Pathology), Mario Kuttke(Research Institute of Molecular Pathology), Lukas Leiendecker(Research Institute of Molecular Pathology), Anais Elewaut(Vienna Biocenter), Maria Novatchkova(Research Institute of Molecular Pathology), Christian Umkehrer(Research Institute of Molecular Pathology), Izabela Kręcioch(Research Institute of Molecular Pathology), Camille L. Gérard(University of Lausanne), Malin Pedersen(Institute of Cancer Research), Thomas Wiesner, Georgina V. Long(The University of Sydney), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Sakari Vanharanta(University of Helsinki), David Hoffmann(Institute of Molecular Biotechnology), Sebastian Carotta(Boehringer Ingelheim (Austria)), Harriet Witthock(Institute of Cancer Research), Michel A. Cuendet(SIB Swiss Institute of Bioinformatics), Richard A. Scolyer(The University of Sydney), Johannes Zuber(Research Institute of Molecular Pathology), Inês Pires da Silva(The University of Sydney), James S. Wilmott(The University of Sydney)
Cited by 196
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
|Immunity|2013|4.7k
Metastatic colonization by circulating tumour cells
|Nature|2016|2k